iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Sees Large Decline in Short Interest

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNAGet Free Report) saw a large decrease in short interest in July. As of July 31st, there was short interest totaling 15,622 shares, a decrease of 72.6% from the July 15th total of 57,108 shares. Based on an average daily volume of 28,692 shares, the short-interest ratio is presently 0.5 days. Currently, 0.3% of the company’s stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently raised its position in iShares Genomics Immunology and Healthcare ETF stock. Ameriprise Financial Inc. lifted its position in shares of iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNAFree Report) by 8.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 71,473 shares of the company’s stock after purchasing an additional 5,540 shares during the period. Ameriprise Financial Inc. owned 1.42% of iShares Genomics Immunology and Healthcare ETF worth $1,688,000 at the end of the most recent quarter.

iShares Genomics Immunology and Healthcare ETF Stock Down 0.0%

Shares of NYSEARCA:IDNA traded down $0.01 during midday trading on Friday, hitting $35.23. The stock had a trading volume of 48,317 shares, compared to its average volume of 43,659. iShares Genomics Immunology and Healthcare ETF has a 12 month low of $22.12 and a 12 month high of $35.51. The business’s 50-day simple moving average is $32.61 and its 200-day simple moving average is $30.59. The company has a market cap of $207.86 million, a P/E ratio of 14.76 and a beta of 0.93.

About iShares Genomics Immunology and Healthcare ETF

(Get Free Report)

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.

Featured Stories

Receive News & Ratings for iShares Genomics Immunology and Healthcare ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Genomics Immunology and Healthcare ETF and related companies with MarketBeat.com's FREE daily email newsletter.